Skip to main content

Table 1 Main characteristics of included studies

From: Hydroxyethyl starch 130/0.4 for volume replacement therapy in surgical patients: a systematic review and meta-analysis of randomized controlled trials

Trail Single/multicenter Country Type of surgery No. of patients Comparators Volume of HES 130/0.4 GDFT Outcomes Jadad score
Alavi, 2012 Single Iran Cardiac 92 RL, 4% gelatin 1320 ± 250 mL No Mortality 3
Duncan, 2020 Single USA Cardiac 141 5% HA 500 (400–750) mL No AKI, RRT 5
Feldheiser, 2013 Single Germany Gynecological 50 Balanced crystalloid Not available Yes Mortality, AKI 4
Futier, 2020 Multi France Abdominal 775 0.9% saline 1000 (750–1500) mL Yes Mortality, AKI, RRT 5
Ghodraty, 2017 Single USA Abdominal 91 RL 10.4 ± 4.1 mL/kg No AKI 5
Godet, 2008 Multi France Vascular 65 3% gelatin 1431 ± 731 mL (19.7 ± 9.9 mL/kg) No Mortality, AKI, RRT 4
Gondos, 2010 Multi Hungary mixed 200 RL, 4% gelatin, 5% HA 10 ml/kg No Mortality 3
Hamaji, 2013 Single Brazil Orthopedic 48 RL 15 ml/kg No Mortality, AKI 4
Hung, 2014 Single China abdominal 80 RL 999.1 ± 369.3 mL No Mortality, AKI 4
Joosten, 2018 Multi Belgium Abdominal 160 Balanced crystolloid 900 (400–1300) mL Yes Mortality, AKI ,RRT 5
Kabon, 2019 Multi Austria, USA Abdominal 1057 RL 1000 (500–1500) mL Yes Mortality, AKI, RRT 5
Kammerer, 2018 Single Germany Urological 100 5% HA 2955 ± 1043 mL No AKI 3
Lee, 2011 Single Republic of Korea Cardiac 106 Crystalloid (plasma solution A) 1458 ± 465 mL No AKI, RRT 1
Lindroos, 2013 Single Finland Neurological 30 RL 464 ± 284 mL Yes Mortality, AKI 3
Mahmood, 2007 Single UK Vascular 62 HES 200/0.62, 4% gelatin 3911 ± 1783 mL No Mortality, RRT 3
Ooi, 2009 Single Malaysia Cardiac 90 4% gelatin 1942.3 ± 1046.1 mL No Mortality 2
Rasmussen, 2014 Single Denmark Abdominal 33 RL 2605 ± 512 mL Yes Mortality 5
Skhirtladze, 2014 Single Austria Cardiovascular 236 RL, 5% HA 42 (35–48) mL/kg
2500 (2250 –2750) mL
No RRT 5
Szturz, 2014 Single Czech Republic Urological 115 RL 1500 (400–3500) mL Yes Mortality 5
Tyagi, 2019 Single India Orthopedic 38 RL 689 ± 394 mL Yes AKI 5
Van der Linden, 2005 Single Belgium Cardiac 132 3% gelatin 21.3 ± 8.3 mL/kg Yes Mortality 3
Verheij, 2006 Single Netherlands Cardiovascular 67 0.9% saline, 4% gelatin, 5% HA 1600 (750–1800) mL No Mortality 3
Yang, 2011 Single China Abdominal 90 RL, 20% HA 3484.6 ± 1072.5 mL No Mortality 2
Yates, 2014 Single UK Abdominal 202 Balanced crystalloid 1875 (1500–3000) mL Yes Mortality, AKI 5
Zhang, 2012 Single China Abdominal 60 RL 865.0 ± 297.4 mL Yes Mortality, AKI 5
  1. RL Ringer’s Lactate solution, HA human serum albumin, AKI acute kidney injury, RRT renal replacement therapy, CVP central venous pressure, SV stroke volume, SVV stroke volume variation, GDFT goal-directed fluid therapy, MAP mean arterial pressure, POD postoperative day